Faculty of Health and Medical Sciences, University of Surrey, Guildford, United Kingdom.
Am J Hosp Palliat Care. 2022 Jul;39(7):838-846. doi: 10.1177/10499091211043079. Epub 2021 Sep 7.
Malignant bowel obstruction is a common cause of morbidity and mortality in patients with advanced ovarian cancer. Many patients aren't suitable for, or decline, surgical decompression. The outcomes for this frail group of patients are not well characterized.
To evaluate survival outcomes of ovarian cancer patients who undergo non-surgical management of malignant bowel obstruction.
Systematic review and meta-analysis.
Online literature search of Pubmed, Embase and Medline libraries up until December 2020. Searching abstracts of scientific meetings, reference lists of included studies and contacting experts in the field.
Studies that investigated non-surgical management of confirmed bowel obstruction in advanced ovarian cancer patients were included. All levels of evidence including RCTs, cohort studies and case-series if they included greater than 5 patients.
The studies were independently chosen by two reviewers who extracted and analyzed the data separately through OpenMeta Analyst software. Study quality was assessed using the JADAD score and the Newcastle Ottawa Score.
24 studies met the eligibility criteria for the systematic review and 9 for the meta-analysis. Median survival of patients managed non-surgically for bowel obstruction was 44 days (95% CI 38-49 days, I = 0%, P = 0.128).
The quality of studies was relatively low, however the evidence shows that non-surgical management of bowel obstruction results in a short life expectancy but with controlled symptoms. Where quality of life is the main concern, this may be a feasible and effective strategy.
恶性肠梗阻是晚期卵巢癌患者发病率和死亡率的常见原因。许多患者不适合或拒绝手术减压。这组脆弱患者的预后情况尚未得到很好的描述。
评估接受非手术治疗恶性肠梗阻的卵巢癌患者的生存结果。
系统评价和荟萃分析。
截至 2020 年 12 月,在 Pubmed、Embase 和 Medline 库中进行在线文献检索。检索科学会议摘要、纳入研究的参考文献列表,并联系该领域的专家。
纳入研究调查了晚期卵巢癌患者确诊的肠梗阻的非手术治疗。包括随机对照试验、队列研究和病例系列研究在内的所有证据级别,如果纳入患者超过 5 例。
两位评审员独立选择研究,并通过 OpenMeta Analyst 软件分别提取和分析数据。使用 JADAD 评分和纽卡斯尔渥太华量表评估研究质量。
24 项研究符合系统评价的纳入标准,9 项研究符合荟萃分析的纳入标准。非手术治疗肠梗阻的患者中位生存期为 44 天(95%CI 38-49 天,I = 0%,P = 0.128)。
研究的质量相对较低,但证据表明,非手术治疗肠梗阻会导致预期寿命较短,但症状得到控制。如果生活质量是主要关注点,这可能是一种可行且有效的策略。